RLMDRELMADA THERAPEUTICS, INC.


$ 3.18 $ -0.06 (-1.85 %)    

Tuesday, 21-May-2024 12:13:59 EDT
QQQ $ 454.82 $ 1.01 (0.22 %)
DIA $ 398.57 $ -0.09 (-0.02 %)
SPY $ 530.36 $ 0.96 (0.18 %)
TLT $ 91.26 $ 0.45 (0.49 %)
GLD $ 225.37 $ -0.69 (-0.31 %)
$ na
$ 3.24
$ 0.00 x 0
$ 0.00 x 0
$ 3.14 - $ 3.24
$ 2.36 - $ 7.22
63,353
na
97.76M
$ 0.95
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 relmada-therapeutics-q1-2024-gaap-eps-072-beats-084-estimate

Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of ...

 relmada-therapeutics-q4-eps-084-misses-083-estimate

Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate o...

 earnings-scheduled-for-march-19-2024

Companies Reporting Before The Bell • Tencent Music Enter Gr (NYSE:TME) is projected to report quarterly earnings at $0.14 per...

 relmada-therapeutics-and-2-other-penny-stocks-insiders-are-buying

The Dow Jones index closed lower by more than 300 points on Wednesday. When insiders purchase or sell shares, it indicates thei...

 why-mobileye-global-shares-are-trading-lower-by-over-23-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23...

 relmada-therapeutics-q3-eps-073-beats-091-estimate

Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of ...

 earnings-scheduled-for-november-8-2023

Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.

 relmada-therapeutics-to-present-new-preclinical-data-on-its-psilocybin-program-at-aasld-the-liver-meeting-2023

Low-dose psilocybin generated statistically significant reductions in liver fat content, plasma glucose levels and body weight ...

 relmada-therapeutics-lead-candidate-shows-promise-in-pivotal-depression-study

Relmada Therapeutics Inc (NASDAQ: RLMD) announced efficacy results for the de novo (or new to treatment) patients (204 patients...

 relmada-therapeutics-announces-efficacy-and-safety-results-from-the-phase-3-long-term-study-of-rel-1017-in-major-depressive-disorder

Patients newly treated with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvements in...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION